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Summary 
Objective A recently discovered myokine, irisin, may have an important role in energy 
metabolism. This study aimed to evaluate the relationship between this hormone and the 
lipid profile of Metabolic Syndrome (MetS) patients following a hypocaloric diet. 
Design Ninety-three Caucasian adults (52 men/41 women) diagnosed with MetS 
followed an 8-week-long energy restricted programme (-30% of the energy 
requirements). Anthropometric measurements, biochemical markers and plasma irisin 
levels were analysed before and after the nutritional intervention. 
Results Global plasma irisin levels were significantly reduced at the end of the study   
(-72·0 ± 100·9 ng/mL, p < 0·001) accompanying the weight loss (-6·9%). The depletion 
of irisin significantly correlated with changes in some atherogenic-related variables: 
total cholesterol (B = 0·106, p = 0·018), total cholesterol/high density lipoprotein-
cholesterol ratio (B = 0·002, p = 0·036), low density lipoprotein-cholesterol (B = 0·085, 
p = 0·037) and apolipoprotein B (B = 0·052, p = 0·002), independently of changes in 
body weight. 
Conclusions An association between the reduction of plasma irisin levels and the 
depletion of important lipid metabolism biomarkers was observed in patients with MetS 
undergoing an energy restricted programme. 
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Introduction 
Irisin is a recently discovered myokine, proteolytically processed from the product of 
the fibronectin type 3-domain containing protein 5 (FNDC5) gene1, with a possible role 
in the regulation of energy metabolism. As a novel hormone, several studies are being 
carried out in order to understand its different functions. Irisin has been reported to be 
expressed in skeletal muscle and to participate in white fat browning2. It might also 
have an antidiabetic role by improving glucose homeostasis3. Also, an inverse 
association with liver fat content has been described4 and as irisin increases with 
exercise2,5, a relation with follistatin, a peptide that regulates muscle growth, has been 
also shown6. Furthermore, an association between irisin and the lipid profile has also 
been described. However, results from the different studies on the target do not reach an 
agreement. This situation may be due to the fact that the studies have been carried out in 
different populations under different conditions.  
In this context, the increasing prevalence of metabolic syndrome (MetS) is considered a 
major concern for public health authorities; they regard MetS as an important burden 
with relevant adverse features and complications7. Among the different metabolic 
abnormalities comprising the MetS, excessive adiposity and dyslipidemia have been 
considered of major clinical relevance due to the well-established relations with 
diabetes and coronary events8,9. Hence, much scientific effort is currently being directed 
to detect, treat and prevent MetS manifestations, focusing on decreasing body 
weight10,11 and lowering the associated risks of lipid metabolism abnormalities12. In 
light of this, the present study aimed to investigate the possible relationships of this 
novel myokine (irisin) with the lipid profile of patients suffering MetS under a caloric-
restricted programme: the RESMENA-S (Metabolic Syndrome Reduction in Navarra-
Spain) project (www.clinicaltrials.gov; NCT01087086).  
Materials and methods 
Study design 
This research reports the findings of a sub-analysis of the first 8-weeks of a nutritional 
intervention within the RESMENA-S project, which has been previously described in 
detail13,14. Briefly, the study was a randomised, controlled trial that compared the effects 
of two hypocaloric (- 30% of the studied requirements) dietary strategies, control and 
RESMENA diets, on MetS, described elsewhere14,15. The control diet was based on the 
American Heart Association guidelines16, including 3–5 meals per day, a macronutrient 
distribution of 55% total caloric value (TCV) from carbohydrates, 15% from proteins 
and 30% from lipids, as well as a healthy fatty acid (FA) profile and a cholesterol 
consumption below 300 mg/day. The RESMENA diet was characterised by a higher 
meal frequency, consisting of seven meals per day and having a different macronutrient 
distribution which was as follows: 40% TCV from carbohydrates, 30% from proteins 
and 30% from lipids.  
Among 109 volunteers with MetS symptoms enrolled in the RESMENA-S study, a total 
of ninety-three Caucasian adults (52 men/ 41 women) diagnosed with MetS according 
to the International Diabetes Federation criteria, started the intervention.  Eighty-four 
completed the 8-week intervention and were included in the final statistical analysis 
(figure 1). Participants were asked to maintain their usual physical activity, which was 
controlled by a 24-h physical activity questionnaire both at the beginning and at the end 
of the study. 
This study followed the CONSORT 2010 criteria18, and was conducted according to the 
guidelines laid down in the Declaration of Helsinki. Informed written consent was 
obtained from all the volunteers before starting the intervention trial 
(www.clinicaltrials.gov; NCT01087086) and the study was approved by the Research 
Ethics Committee of the University of Navarra (ref. 065/2009).  
Anthropometric and biochemical measurements 
Anthropometric and body composition measurements were taken in fasting conditions 
as was previously described . Body weight was assessed to the nearest 0·1 kg using 
bio-impedance (TANITA SC-330; Tanita Corporation) equipment. BMI was calculated 
as the body weight divided by height squared (kg/m ). Waist and hip circumferences 
were measured using a commercial measuring tape and following validated protocols . 
Total body fat mass and android fat mass were determined using dual-energy X-ray 
absorptiometry (Lunar iDXAe, software version 6·0; GE Healthcare). Systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) were assessed using a digital 
monitor (Medisana AG, MTC) according to the World Health Organization criteria. 
Serum total cholesterol (TC), 
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high density lipoprotein-cholesterol (HDL-c), 
triglycerides (TG), free fatty acids (FFA) and glucose concentrations were measured 
using a Pentra C-200 auto-analyser (Horiba ABX) with specific kits. Low density 
lipoprotein-cholesterol (LDL-c) levels were calculated using the Friedewald formula : 
LDL-c = TC - HDL-c - TG/5. 
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Apolipoprotein B (Apo B) values were measured with a 
specific kit (Tina-quant Apolipoprotein B version 2) using a Model 904 Modular 
Roche/Hitachi autoanalyser (Roche Diagnostics). 
The quantitative measurement of irisin in human plasma samples was performed using a 
commercial enzyme-linked immunosorbent assay (ELISA) kit directed against amino 
acids 31-143 of the FNDC5 protein according to the manufacturer’s instructions (Irisin 
ELISA Kit EK-067-52; Phoenix Pharmaceuticals, INC, CA). Absorbance from each 
sample was measured in duplicate using a spectrophotometric microplate reader at 
wavelength of 450nm (Versamax Microplate Reader; Associates of Cape Cod 
Incorporated, East Falmouth, MA). This test provided a range of detection of 0·066-
1024 ng/mL and exhibited an inter and intra-assay coefficient of variation of 6-10%. 
The samples were kept at -80ºC and were analysed during the month following the end 
of the study. 
Statistical analyses 
This study is a sub-analysis of data obtained as a part of the RESMENA-S study. 
Statistical tests were performed using the SPSS 15·0 software for Windows (SPSS 
Ibérica, Madrid, Spain). Mean values and standard deviations of the measured variables 
were reported. Differences were considered statistically significant at p < 0·050.  
Based upon previous studies , the required sample size (forty per group) in the 
randomised controlled trial was calculated to detect a difference of 4·3 cm, with a 
variation of ± 6·8 cm between the groups in the reduction of waist circumference with a 
p < 0·05 and a power of 80 %. The estimated dropout rate was 25%, and the initial 
number of recruited subjects was 109. The intervention trial started with ninety-three 
subjects presenting MetS and ended with forty per group (figure 1).  
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Differences between the beginning and the end of the intervention were analysed in 
each dietary group by a paired t-test. Differences in changes between the dietary groups 
were assessed by analyses of covariance after adjusting for baseline values of each 
variable. One-tailed Pearson correlation analysis was used to test for a positive 
relationship between percentage of depletion of irisin levels and percentage of body 
weight reduction with regard to baseline values. Pearson correlation analyses were 
performed in order to assess the potential relationships and associations among the 
changes in plasma irisin levels and co-variates of interest. Finally, linear regression 
analyses, adjusted for body weight variation, were applied to individually study 
associations between the changes in plasma irisin levels and variations in lipid profile 
variables (TC, HDL-c, LDL-c, TC/HDL-c ratio, Apo B, TG and FFA).  
Results 
Anthropometric and biochemical markers 
Both dietary strategies proved to be effective in improving anthropometric and 
biochemical markers (table 1). Overall, control and RESMENA groups reduced body 
weight, BMI, waist circumference, waist to hip ratio (WHR)  as well as total  and 
android  fat mass percentages with a statistically significant p value < 0·001. Both 
dietary strategies also resulted in a decline in the SBP and DBP measurements. As for 
biochemical markers, Apo B, TG and glucose levels were significantly diminished in 
both dietary groups. TC, HDL-c and LDL-c reductions only reached statistical 
significance in the control subjects, although they decreased in both dietary groups. 
Indeed, no statistically significant differences between control and RESMENA dietary 
strategies were observed in any of the anthropometric and biochemical variables (table 
1). Therefore, both dietary groups were merged for further analyses. 
Regarding plasma irisin levels, they presented a statistically significant reduction in 
both dietary groups (-87·3 ± 114·2 ng/mL control, -57·4 ± 85·1 ng/mL RESMENA, both 
p < 0·001), but no differences were found between either nutritional patterns (table 1) or 
between genders. 
Association between irisin and lipid profile 
In the whole sample, a positive relationship was found between the percentage of 
depletion of irisin levels and the percentage of body weight reduction as compared to 
baseline values, resulting in a trend towards significance (r = 0·165, p = 0·069). 
Moreover, significant associations between the reduction in irisin levels and a depletion 
in TC (r = 0·269, p = 0·014), TC/HDL-c (r = 0·241, p = 0.029), LDL-c (r= 0·239, p = 
0·031) and Apo B (r = 0·345, p = 0·002) were observed. However, changes in total lean 
mass, SBP, DBP, HDL-c, TG, FFA, glucose or activity level did not show a significant 
correlation with the irisin variation (table 2). 
Linear regression analyses, adjusted for body weight variation, were applied to evaluate 
the relationship between changes in plasma irisin levels (ng/mL) and lipid profile 
biomarker variation (mg/dL), independently of changes in body weight. Among these, 
changes in TC (B = 0·106, CI95%: 0·019 to 0·193, p = 0·018, r2 = 0·105), TC/HDL-c 
ratio (B= 0·002, CI95%: 0·001 to 0·004, p = 0·036, r2 = -0·100), LDL-c (B= 0·085, 
CI95%: 0·005 to 0·165, p = 0·037, r2 = 0·050) and Apo B (B = 0·052, CI95%: 0·020 to 
0·084, p = 0·002, r2 = 0·107) were statistically related to plasma irisin variations (figure 
2). However, for HDL-c (p = 0·978), TG (p = 0·204) or FFA (p = 0·364) this association 
was not statistically significant. 
Discussion 
The recently discovered myokine, irisin, has received much attention due to the fact that 
it has been involved in the regulation of human energy metabolism23,24. In the present 
study it was found that the variation in atherogenic parameters paralleled the changes in 
irisin levels after weight loss therapy. Therefore, these results suggest that irisin could 
also be involved in fat metabolism homeostasis or lipid disorders. 
 As has been found in other studies concerning hypocaloric diets25, both control and 
RESMENA dietary strategies proved to be effective in improving MetS abnormalities. 
This conclusion is based on the fact that the general anthropometric and biochemical 
parameters of the volunteers that are related to MetS were lowered. 
Interestingly, irisin levels decreased in both dietary groups after the 2-month-long 
hypocaloric intervention. Relevant investigations have reported that irisin levels are 
elevated under obesity and on MetS patients or reduced under anorexia or after weight 
loss26,27. In order to elucidate if the causes of the observed irisin depletion were in line 
with the aforementioned investigations, the association between this hormone’s 
variation and changes in body weight, was evaluated. It is worth noting that, a trend 
towards significance was found in the relationship between the percentage change of 
irisin levels and the percentage variation of body weight.  
The main objective of the current analysis was to evaluate the potential relationships 
between changes in atherogenic parameters and the variation in irisin levels after a 
weight loss programme. However, irisin changes can also be related to lean mass and/or 
exercise level, since it is considered a myokine2, ,5 28. A positive correlation between 
irisin and blood pressure has also been observed27,29. Moreover, it has previously been 
described that plasma glucose could influence serum irisin levels30. Therefore, in order 
to exclude possible confounding variables, correlation analyses were performed 
between changes in plasma irisin levels and changes in total lean mass, blood pressure, 
glucose concentrations or activity level. Nevertheless, no significant relationships were 
found in this experimental trial. 
After finding irisin depletion in the MetS population at the end of the weight loss 
programme, the analysis of potential relationships of this myokine with the changes in 
the lipid profile was aimed. Associations between this myokine levels and plasma 
cholesterol have been previously described in other studies, but there is no general 
agreement among investigations concerning obese subjects. While Liu et al.29 showed a 
positive correlation between this myokine and TC, Huh et al.31 reported a negative 
association and Wen et al.32 observed a positive correlation between irisin and HDL-c, 
but not with TC or LDL-c. Furthermore, to our knowledge, this is the first report that 
shows a relationship between irisin and the atherogenic index TC/HDL-c or Apo B 
levels. Additionally, it should be mentioned that all the above cited studies were cross-
sectional studies, while our findings belong to a weight-loss intervention trial where an 
association between irisin changes and TC, LDL-c, TC/HDL-c and Apo B variations is 
reported.  
Although the exact mechanisms of irisin action remain unclear, these findings suggest 
that irisin may participate in the regulation of lipid metabolism. We speculated that 
given irisin’s putative role as a “metabolism-activator”, changes in irisin concentration 
might reflect a response to metabolic (or atherogenic) burdens. This outcome might 
therefore explain our observation of a positive correlation between irisin and 
atherogenic factors such as total cholesterol and Apo B. Moreover, a resistance 
phenomenon could not be excluded. Indeed, irisin could follow a similar pattern as 
leptin or insulin, which are elevated in obese subjects and reduced after subjects 
undergo a hypocaloric diet33, as other authors have also suggested27,34. 
In addition to the limitations of a post-hoc analysis, it should be mentioned that due to 
the relatively small sample size, type 2 errors cannot be excluded. Moreover, the 
investigation was performed on patients suffering MetS following an energy restricted 
diet; therefore, further studies should be carried out in order to determine whether irisin 
changes are related to lipid profile in other populations.  
In summary, this study shows a positive relationship between the decrease in irisin 
levels and reductions in plasma lipid profile markers in MetS patients following an 
energy restricted programme. Further investigations into this myokine might be a good 
target to better understand not only energy expenditure, as was initially proposed1,2, but 
also the atherogenic dyslipidemia process, which is one of the main concerns of the 
MetS and obesity conditions. 
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